Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development

LONDON, February 10 - London Genetics Limited, an expert in the use of
pharmacogenetics in clinical drug discovery and development, is pleased to
announce the launch of its expanded web site. The site, which was designed by
Opus Design Consultants, highlights how pharmacogenetics can help to target
drugs to those patients most likely to benefit, and to increase safety and
cost-effectiveness. Working in partnership with its seven founding academic
institutions, all with expertise in genetics research, London Genetics can
help biopharmaceutical companies generate the data they need from their
clinical drug development activities.

Pharmacogenetics is the study of how our genetic make-up
affects the way in which we metabolise and respond to drugs. As a result, it
is expected to play a key role in the future of drug development and
healthcare delivery as the industry faces increasing pressure to replenish
its pipeline, and improve drug safety and value. Through delivery of
strategic advice on the application of pharmacogenetics in drug development,
London Genetics can help companies meet this need for smarter and more
efficient drug development. The company has broad therapeutic experience with
a focus on cardiovascular drugs and cardiovascular safety.

The importance of this emerging technology is increasingly
recognised by leading industry commentators and executives. In his
'Predictions for 2010 - Gazing into the Crystal Ball'[1], Steven Burrill of
life sciences specialist Burrill & Co speculates that 'We will continue to
see companies both large and small build their business models around the
technologies that are driving personalized medicine. Targeted therapies will
be developed that focus more on subpopulations rather than the traditional
one-size fits all model.'

In addition to the launch of the new web site
(www.londongeneticslimited.com), London Genetics will be highlighting
its activities at several conferences globally over the coming months. These
include the European Life Science CEO Forum (February 11-12, Zurich,
Switzerland[2]), DIA 22nd Annual EuroMeeting (March 8-10, Monaco[3]) and
BioTrinity 2010 (April 12-14, Newbury, UK[4]).

Dominique Kleyn, CEO, commented 'London Genetics is delighted
to launch its new web site, which provides a wealth of information on the
importance of pharmacogenetics. It is an important business development tool
for us going forward, as we continue our partnering programme and work with
the biopharmaceutical industry on increasing the effectiveness of drug
development.'

[1] www.burrillreport.com/article-2024.html

[2] European Life Science CEO Forum, February 11-12, Zurich, Switzerland
www.sachsforum.com/zurich_elsceo10/index.html

[3] DIA 22nd Annual EuroMeeting, March 8-10, Monaco
www.diahome.org/diahome/FlagshipMeetings/home.aspx?meetingid=20292

[4] BioTrinity 2010, April 12-14, Newbury, UK
www.biotrinity.com/silverstripe/

Notes to Editors:

About London Genetics

London Genetics Limited, a not-for-profit company, is an
expert in the use of pharmacogenetics in clinical drug discovery and
development. Established in 2007 with funding from the London Development
Agency, its seven founding partners are leading London academic and medical
institutions with clinical and genetic expertise and significant patient
resources. The company provides pharmaceutical and biotechnology companies
with access to this expertise and resource, as well as providing strategic
advice on the application of pharmacogenetics for successful drug
development. LGL has broad therapeutic expertise with a focus on
cardiovascular disease and drug side-effects of a cardiovascular nature.
Recent agreements developed by London Genetics include a collaboration
between the International Serious Adverse Events Consortium, St George's
University of London and the Drug Safety Research Unit at Southampton, UK.
The parties are working on genetic markers for drug-induced cardiac
arrhythmia. LGL is based at the Imperial College Incubator in London, and has
ISO 9001 accreditation. For further information, please go to
www.londongeneticslimited.com

About pharmacogenetics

Genetic differences between individuals means that drug
response rates are often variable across a population, and this has
significant healthcare cost effectiveness implications. Pharmocogenetics, the
study of the clinical consequences of genetic differences in the way people
metabolise and respond to drugs, is expected to generate better understanding
of how drugs work in the body, and therefore give insight into how to develop
more efficacious and safer drugs. It also has implications for product life
cycle management and the revitalisation of drugs which previously failed in
clinical trials. With drug development costs rising and R&D productivity
falling, plus increased regulator focus on safety and cost-effectiveness,
pharmacogenetics is expected to become increasingly important in drug
development. The FDA and the EMEA have recognised this in their Critical Path
Initiative and Road Map respectively.

    For further information or to meet us at conferences please contact:

    London Genetics Ltd

    Dominique Kleyn, CEO                                   +44(0)207-594-1838

    Emma Palmer Foster, Strategic Communications Consultant +44(0)7880-787185

    communications@londongenetics.com

For further information or to meet us at conferences please contact: London Genetics Ltd, Dominique Kleyn, CEO, +44(0)207-594-1838; Emma Palmer Foster, Strategic Communications Consultant, +44(0)7880-787185, communications at londongenetics.com